The unchanged EPS year-over-year suggests stability in Akari Therapeutics' financial performance. However, the lack of growth could be perceived neutrally by investors, as it indicates neither deterioration nor improvement in profitability. The relevance is high as the news directly pertains to AKTX's financial results. The importance is marked at 75, considering that earnings reports are crucial for investors, but the lack of change might not significantly alter investment decisions. The confidence level is at 90, based on the clear and direct impact of earnings reports on stock perception.